Related Experiment Video

Updated: Jun 19, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer

Bruno de Paula1, Olivier Cexus2, Paul Townsend2

  • 1School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guilford, UK; Núcleo de Pesquisa Clínica, Hospital do Câncer III, Instituto Nacional de Câncer - INCA, Brazil.

Asian Journal of Surgery
|July 23, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Her2-positive breast cancerPathological complete response rateZoledronic acid

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K